News & Topics
News&Topics

2020 / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010 / 2009 / 2008 / 2007 / 2006 / 2005

2020.10.13
Exercise of the 51st Stock Acquisition Rights and Revision to the Specific Uses and Amounts of Funds Raised through the 50th and 51st Stock Acquisition Rights
2020.09.23
SymBio Receives Approval of TREAKISYM Ready-To-Dilute (RTD) Formulation
2020.09.17
Analyst Report[Update report] (Shared Research)
2020.09.17
Revision to Earnings Forecasts for FY 2020 and Mid-Range Plan (FY 2020 to FY 2022)
2020.09.10
Analyst Report[Commercial outlook] (EDISON)
2020.09.09
Last Patient Last Visit (“LPLV”) Achieved in Clinical Study for TREAKISYM Rapid Infusion Liquid Formulation
2020.09.07
Preparation for Sales & Marketing by SymBio's Own Sales Organization
2020.09.01
Final Arbitration Award in Dispute against The Medicines Company
2020.08.25
Analyst Report[Full report] (Shared Research)
2020.08.25
Onconova Therapeutics Announces Topline Results from the Pivotal Phase 3 INSPIRE Trial for Higher-Risk Myelodysplastic Syndromes (HR-MDS)
2020.08.05
Analyst Report[Update report] (Shared Research)
2020.08.05
Arbitration Award in Dispute against The Medicines Company
2020.08.05
Summary of Financial Statements for the First Six Months of Fiscal Year Ending December 31, 2020 [Japanese GAAP] (Non-consolidated)
2020.08.05
Notice Concerning Non-operating Expenses
2020.08.05
SymBio Announces Global Development Plan of Anti-viral Drug Brincidofovir IV For Adenovirus Infectious DiseaseAfter Hematopoietic Stem Cell Transplantation
2020.07.30
Onconova Therapeutics Announces that the Required Number of Survival Events Has Been Reached for the Pivotal Phase 3 INSPIRE Trial Data Analysis
2020.07.28
Onconova Therapeutics Submits Application for Rigosertib to Participate in Federally Funded Human Studies in COVID-19 Disease
2020.07.13
SymBio submits Partial Change Application for use of TREAKISYM in combination with polatuzumab vedotin and rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2020.07.09
Onconova Therapeutics Announces Publication of Phase 1 Results in Leukemia Research Exploring Oral Rigosertib in Combination with Azacitidine in Higher-Risk MDS
2020.06.23
Onconova Therapeutics Announces the Initiation of a Phase 1/2a Study of Rigosertib plus Nivolumab for the Treatment of KRAS+ Lung Adenocarcinoma
2020.06.16
Analyst Report[Full report] (Shared Research)
2020.06.01
Completion, Monthly Exercise Status and Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.06.01
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.26
Analyst Report[Clinical update] (EDISON)
2020.05.19
Analyst Report[Earnings and regulatory update] (EDISON)
2020.05.15
The 25th Congress of the European Hematology Association (25th EHA Annual Congress) Accepts Abstract for Phase III Clinical Trial of TREAKISYM in Relapsed or Refractory Diffuse Large B-Cell Lymphoma for Publication
2020.05.12
Analyst Report[Update report] (Shared Research)
2020.05.11
SymBio submits Partial Change Application for use of TREAKISYM in combination with rituximab as treatment for relapsed or refractory diffuse large B-cell lymphoma
2020.05.11
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.08
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.07
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.05.01
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.30
Chimerix Receives FDA Clearance for Rolling Submission of New Drug Application for Brincidofovir as a Medical Countermeasure for Smallpox
2020.04.30
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Directors
2020.04.24
Notice Concerning Finalized Details on Issuance of Stock Acquisition Rights (Stock Option) to the Company’s Employees
2020.04.22
Notice of Change (Retirement) of Director
2020.04.21
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.20
Analyst Report[COMPANY RESEARCH AND ANALYSIS REPORT] (FISCO)
2020.04.14
Notice of the Large Volume Exercise of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.04.07
Analyst Report[Basic Report] (Fair Research)
2020.04.01
Monthly Exercise Status of the 50th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.03.27
Notice of Shareholder Voting Results for the 15th Ordinary General Meeting of Shareholders
2020.03.26
Analyst Report[Full report] (Shared Research)
2020.03.26
Notice of Members of the Board of Director, Substitute Member of the Audit & Supervisory Board and Corporate Officers Appointment
2020.03.26
Notice Concerning the Issuance of Stock Acquisition Rights to Directors
2020.03.26
Notice Concerning the Issuance of Stock Acquisition Rights to Employees
2020.03.25
Completion of Patient Enrollment in Clinical Trial for TREAKISYM Rapid Infusion Liquid Formulation
2020.03.25
Onconova Announces Completion of Enrollment in Phase 3 INSPIRE Trial of IV Rigosertib
2020.03.16
Completion of Payment for Subscription for the 50th and 51st Stock Acquisition Rights (with Exercise Price Revision Clauses)
2020.03.06
Information on Shareholders' Meeting: Updated the Page
2020.02.27
Analyst Report[Update report] (Shared Research)
2020.02.27
Notice of the Issuance of the 50th and 51st Stock Acquisition Rights with Exercise Price Revision Clauses and Conclusion of Third-Party Allotment Agreement (Commit Issue Program)
2020.02.27
Notice concerning Nominations for the Board of Directors / the Audit & Supervisory Board / and Substitute Member for the Audit & Supervisory Board
2020.02.12
Completion, Monthly Exercise Status and Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.02.06
Analyst Report[Update report] (Shared Research)
2020.02.06
3 Year Mid-Range Plan: FY 2020 to FY 2022
2020.02.06
Notice Concerning Non-operating Expenses
2020.02.06
Summary of Financial Statements for the Fiscal Year Ended December 31, 2019[Japanese GAAP] (Non-consolidated)
2020.02.03
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.01.15
Notice of the Large Volume Exercise of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment
2020.01.06
Monthly Exercise Status of the 47th Stock Acquisition Rights (with Exercise Price Revision Clauses) Issued by way of Third Party Allotment